We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+37.76%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$4.9B
AUM Growth
+$644M
Cap. Flow
-$263M
Cap. Flow %
-5.37%
Top 10 Hldgs %
40.38%
Holding
132
New
23
Increased
22
Reduced
35
Closed
25
Avg Time Held Equity + Options
8.6 quarters
Top 10 Avg Time Held Equity + Options
7 quarters
Top 20 Avg Time Held Equity + Options
8.2 quarters
Avg Time Held Equity only
8.7 quarters
Top 10 Avg Time Held Equity only
7 quarters
Top 20 Avg Time Held Equity only
8.2 quarters

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$41.7M
2
BMY icon
Bristol-Myers Squibb
BMY
+$37.3M
3
ELV icon
Elevance Health
ELV
+$33.5M
4
HELP
Helus Pharma Inc. Common Stock
HELP
+$24.7M
5
BRKR icon
Bruker
BRKR
+$23.5M

Top Sells

Rank Stock Value
1
TERN icon
Terns Pharmaceuticals
TERN
+$125M
2
RNAM
Avidity Biosciences
RNAM
+$65.8M
3
EXAS icon
Exact Sciences
EXAS
+$51.6M
4
AXSM icon
Axsome Therapeutics
AXSM
+$38.9M
5
SIBN icon
SI-BONE Inc
SIBN
+$38M

Sector Composition

Rank Sector Weight
1 Healthcare 99.3%
2 Miscellaneous 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
EWTX icon
1
Edgewise Therapeutics
EWTX
$3.99B
$385M 7.86%
15,518,492
– –
2021 Q1
19 quarters
LLY icon
2
Eli Lilly
LLY
$1.04T
$324M 6.61%
301,200
– –
2023 Q1
11 quarters
BSX icon
3
Boston Scientific
BSX
$63.3B
$231M 4.71%
2,419,300
-10,000
-0.4% -$980K
2014 Q1
47 quarters
SVA
4
DELISTED
Sinovac Biotech, Ltd
SVA
$184M 3.77%
2,718,735
– –
2022 Q2
14 quarters
EW icon
5
Edwards Lifesciences
EW
$49.3B
$157M 3.21%
1,842,900
+158,900
+9% +$13M
2024 Q4
4 quarters
UPB icon
6
Upstream Bio Inc
UPB
$204M
$155M 3.16%
5,693,589
– –
2024 Q4
4 quarters
ISRG icon
7
Intuitive Surgical
ISRG
$149B
$149M 3.04%
263,400
-23,800
-8% -$12.7M
2013 Q4
48 quarters
SION icon
8
Sionna Therapeutics
SION
$199M
$147M 2.99%
3,561,655
-143,304
-4% -$5.43M
2025 Q1
3 quarters
MBX icon
9
MBX Biosciences
MBX
$2.39B
$124M 2.53%
3,935,203
-67,684
-2% -$1.64M
2024 Q3
5 quarters
ARGX icon
10
argenx
ARGX
$50.4B
$123M 2.51%
146,000
-26,300
-15% -$22.5M
2022 Q1
15 quarters
ELVN icon
11
Enliven Therapeutics
ELVN
$2.9B
$123M 2.5%
7,959,538
– –
2020 Q1
23 quarters
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$29.8B
$115M 2.34%
288,800
-12,800
-4% -$5.66M
2024 Q2
6 quarters
SYK icon
13
Stryker
SYK
$109B
$114M 2.33%
325,000
-34,200
-10% -$12.5M
2020 Q3
21 quarters
SPRY icon
14
ARS Pharmaceuticals
SPRY
$403M
$96.6M 1.97%
8,288,510
– –
2020 Q4
20 quarters
TERN icon
15
DELISTED
Terns Pharmaceuticals
TERN
$87M 1.78%
2,153,300
-5,409,671
-72% -$125M
2021 Q1
19 quarters
IRON icon
16
Disc Medicine
IRON
$2.18B
$84.8M 1.73%
1,067,550
-347,470
-25% -$29.4M
2021 Q1
19 quarters
CAI icon
17
Caris Life Sciences
CAI
$8.4B
$84.1M 1.72%
3,116,011
+81,153
+3% +$2.29M
2025 Q2
2 quarters
NTRA icon
18
Natera
NTRA
$57B
$83.8M 1.71%
365,800
-63,500
-15% -$13.2M
2015 Q3
41 quarters
CMPX icon
19
Compass Therapeutics
CMPX
$159M
$81.7M 1.67%
15,219,994
– –
2021 Q4
16 quarters
GPCR icon
20
Structure Therapeutics
GPCR
$1.59B
$80.8M 1.65%
1,161,803
+22,503
+2% +$919K
2024 Q2
6 quarters
DHR icon
21
Danaher
DHR
$158B
$68.6M 1.4%
299,800
+36,700
+14% +$8.07M
2025 Q3
1 quarter
CGON icon
22
CG Oncology
CGON
$5.56B
$63M 1.29%
1,516,550
-210,300
-12% -$8.7M
2024 Q3
5 quarters
APLS icon
23
DELISTED
Apellis Pharmaceuticals
APLS
$61M 1.25%
2,429,868
+106,500
+5% +$2.5M
2025 Q1
3 quarters
AVBP icon
24
ArriVent BioPharma
AVBP
$801M
$60.9M 1.24%
3,027,328
– –
2024 Q1
7 quarters
CI icon
25
Cigna
CI
$74.6B
$56.4M 1.15%
205,000
+42,200
+26% +$11.8M
2025 Q3
1 quarter
1
2 3 4 5

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q4 2025 Portfolio in Review

As of Q4 2025, OrbiMed held 132 positions worth $4.9B, up 15% from $4.26B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

OrbiMed withdrew a net $263M in Q4 2025, closing 25 positions and reducing 35 holdings. Its most notable exit was SI-BONE Inc, an estimated $38M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in Pfizer worth $41.2M.

  • OrbiMed's largest Q4 2025 buy was Pfizer: 1,652,900 shares worth $41.2M.
  • OrbiMed added most to RAPT Therapeutics in Q4 2025, an estimated $17.3M increase.
  • OrbiMed's biggest Q4 2025 reduction was Terns Pharmaceuticals, cutting an estimated $125M.
  • OrbiMed fully exited SI-BONE Inc in Q4 2025, selling an estimated $38M.
  • OrbiMed's ten largest holdings make up 40% of its $4.9B portfolio in Q4 2025.
  • OrbiMed opened 23 new positions and closed 25 in Q4 2025.
  • OrbiMed's portfolio value rose 15% quarter-over-quarter to $4.9B.

Based on OrbiMed's 13F filing for Q4 2025, filed 17 Feb 2026.